Tribunal Declares Prime Medicine's PM657 Is Within It's "Field" As Defined By Agreement With Beam Therapeutics; Company Owes No Monetary Damages To Beam

-- Arbitration tribunal declared that PM647 is within Prime Medicine’s "Field", confirming Prime Medicine’s right to develop and commercialize PM647 in AATD --

-- Prime Medicine owes no monetary damages to Beam Therapeutics --

-- Prime Medicine plans to submit an IND and/or CTA filing for PM647 in Q3 2026, initial clinical data expected in 2027 --